There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT – Research Report) and Atricure (ATRC – Research Report) with bullish sentiments.
Altimmune (ALT)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Altimmune today and set a price target of $25.00. The company’s shares closed last Friday at $3.57, close to its 52-week low of $2.09.
According to TipRanks.com, Rahimi is a 3-star analyst with an average return of
Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $16.00, implying a 178.7% upside from current levels. In a report issued on November 30, JMP Securities also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s best-performing stocks on TipRanks >>
Atricure (ATRC)
Piper Sandler analyst Matthew O’Brien upgraded Atricure to Buy today and set a price target of $65.00. The company’s shares closed last Friday at $36.57, close to its 52-week low of $32.27.
According to TipRanks.com, O’Brien is a 4-star analyst with an average return of
Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $55.00, which is a 55.5% upside from current levels. In a report issued on November 28, Needham also maintained a Buy rating on the stock with a $49.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALT:
- Altimmune price target raised to $25 from $16 at JMP Securities
- Unusually active option classes on open December 1st
- ‘Impressive’ Altimmune data likely drives strategic interest, says B. Riley
- Altimmune Stock (NASDAQ:ALT) Rallies on Positive Obesity Drug Results
- Altimmune announces results from 48-week MOMENTUM obesity trial
